Senescence of alveolar type 2 (ATII) cells, progenitors of the alveolar epithelium, is implicated in the pathogeneses of idiopathic pulmonary fibrosis (IPF), an aging-related progressive fatal lung disorder with unknown etiology. The mechanism underlying ATII cell senescence in fibrotic lung diseases, however, remains poorly understood. In this study, we report that ATII cells in IPF lungs express higher levels of serpine 1, also known as plasminogen activator inhibitor 1 (PAI-1), and cell senescence markers p21 and p16, compared to ATII cells in control lungs. Silencing PAI-1 or inhibition of PAI-1 activity in cultured rat ATII (L2) cells leads to decreases in p53 serine 18 phosphorylation (p53 S18P ), p53 and p21 protein expressions; an increase in retinoblastoma protein phosphorylation (ppRb); and a reduction in the sensitivity to bleomycin-and doxorubicininduced senescence. Silencing p53, on the other hand, abrogates PAI-1 protein-stimulated p21 expression and cell senescence. In vivo studies, using ATII cell-specific PAI-1 conditional knockout mouse model generated recently in this laboratory, further support the role of PAI-1 in the activation of p53-p21-Rb cell cycle repression pathway, ATII cell senescence, and lung fibrosis induced by bleomycin. This study reveals a novel function of PAI-1 in regulation of cell cycle and suggests that elevation of PAI-1 contributes importantly to ATII cell senescence in fibrotic lung diseases.
Introduction
Cellular senescence, a state of permanent inhibition of cell growth, has been linked to aging and aging-related diseases (Akram et al., 2014) . The mechanisms underlying cellular senescence under either physiological or pathological conditions, however, remain poorly understood. Alveolar type II (ATII) cells can self-renew and also differentiate into type I alveolar epithelial cells and therefore are considered as alveolar progenitor cells (Aoshiba et al., 2003 (Aoshiba et al., , 2013 . ATII cell senescence is evident in fibrotic lung diseases, including IPF (Buckbinder et al., 1995; Chang et al., 2010; Bhandary et al., 2013; Barkauskas & Noble, 2014) , and in experimental fibrosis models (Chao, 2015; Childs et al., 2015) . A current disease paradigm is that lung fibrosis develops as a result of unremitting insults plus genetic and aging-related risk factors, leading to alveolar epithelial cell injuries, which is followed by activation of myofibroblasts and replacement of injured alveolar epithelium with fibrotic tissue, due to a decreased reparative capacity of alveolar epithelium. Elucidation of the mechanisms underlying ATII cell senescence, therefore, may be a key to our understanding of the disease pathogenesis and thus development of effective therapeutics.
Plasminogen activator inhibitor 1 (PAI-1), also known as serpine 1, is a primary inhibitor of tissue type and urokinase type plasminogen activators (tPA and uPA, respectively), which convert plasminogen into plasmin, a serine proteinase playing a major role in fibrinolysis. Besides suppression of fibrinolysis, PAI-1 has many other functions, including modulation of cell adhesion, migration, and proliferation, dependent or independent of its protease inhibitory activity (Chilosi et al., 2013) . Studies from this laboratory and from others have shown that PAI-1 plays a critical role in the development of lung fibrosis, although the mechanism whereby PAI-1 promotes lung fibrosis remains elusive (ElDeiry et al., 1992; Dimri et al., 1995; Citrin et al., 2013; Disayabutr et al., 2016) . Importantly, PAI-1 expression is increased in senescent cells (Elzi et al., 2012) and emerging evidence suggests that PAI-1 is not merely a marker but also a mediator of cell senescence (Fernandez Perez et al., 2010; Eren et al., 2014a,b; Ghosh et al., 2016) . Nonetheless, whether increased PAI-1 expression is responsible for ATII cell senescence in fibrotic lung diseases and, most importantly, how PAI-1 promotes cell senescence remain unclear.
Using IPF lung tissues, cultured ATII cells, and a tamoxifen-inducible, ATII cell-specific PAI-1 conditional knockout mouse model generated recently in this laboratory, we show, in this study, that PAI-1 induces p53, activates p53-p21-Rb cell cycle repression pathway, and mediates bleomycin-and doxorubicin-induced ATII cell senescence both in vitro and in vivo. Suppression of ATII senescence by knocking out the PAI-1 gene is associated with an attenuation of lung fibrosis. These results reveal a novel mechanism whereby PAI-1 regulates cell cycle and suggest that elevated PAI-1 contributes to ATII cell senescence in fibrotic lung diseases.
Results

ATII cells in IPF lungs express higher level of PAI-1 and cell senescence markers p21 and p16
ATII cell senescence is evident in IPF lung. As PAI-1 plays a critical role in cell senescence and in the development of lung fibrosis, we first examined whether senescent ATII cells in IPF lung express higher level of PAI-1. Our results confirm that, compared to ATII cells in control lungs, ATII cells in IPF lungs express higher levels of PAI-1 (Hogan et al., 2014) as well as p21 and p16 (Chang et al., 2010; Barkauskas & Noble, 2014) , two-cell senescence mediators. These results suggest that increased PAI-1 expression may contribute to ATII cell senescence in IPF.
Silencing PAI-1 with PAI-1 siRNA/shRNA reduces p53 and p21 expressions, increases Rb protein phosphorylation, and attenuates bleomycin-induced ATII cell senescence Although PAI-1 expression is increased in ATII cells in IPF lung, whether increased PAI-1 is responsible for, and how PAI-1 induces, ATII cell senescence are unknown. p53 is a master cell cycle regulator, which induces cell cycle arrest or senescence mainly through inducing p21, a cyclin-dependent kinase inhibitor. p53 expression is increased in ATII cells in IPF lung (Buckbinder et al., 1995; Barkauskas & Noble, 2014) . To determine whether increased PAI-1 expression is responsible for ATII cell senescence in fibrotic lungs and whether PAI-1 induces ATII cell senescence through increasing p53, rat ATII (L2) cells were treated with bleomycin. The results show that treatment of L2 cells with bleomycin significantly increases the protein levels of PAI-1, p53, and p21 as well as the activity of senescence associated beta-galactosidase (SA-b-gal), a marker of cell senescence (Fig. 1A,B) . Silencing PAI-1 with PAI-1 siRNA, on the other hand, dramatically reduces the basal levels of p53 and p21 proteins in L2 cells (Fig. 1C) . These results indicate that PAI-1 positively regulates p53 and p21 expression and may mediate bleomycin-induced ATII cell senescence through activating p53-p21 pathway.
To further delineate the role of PAI-1 in ATII cell senescence, L2 cells were stably transfected with PAI-1 shRNA or nontarget shRNA (NT shRNA, control) and then treated with bleomycin. Western blotting results show that silencing PAI-1 with PAI-1 shRNA significantly increases the basal level of phosphorylated retinoblastoma protein (ppRb), attenuates bleomycin-mediated increases in p53 serine 18 phosphorylation (p53 S18P ), p53 and p21 protein expression, and partially restores bleomycin-mediated suppression of ppRb (Fig. 1D,J) . The ratio of p53 S18P to p53 is significant increased with bleomycin treatment;
silencing PAI-1, however, attenuates bleomycin-stimulated increase in the ratio (Fig. 2D,H) , suggesting that PAI-1 stimulates p53 phosphorylation at serine 18, a critical phosphorylation site for the stability of p53 protein (Huang et al., 2012 (Huang et al., , 2015 , independence of its effect on p53 protein abundance. Associated with inhibition of p53 and p21 expression as well as stimulation of Rb phosphorylation, PAI-1 shRNA ameliorates bleomycin-mediated suppression of proliferating cell nuclear antigen (PCNA) expression (Fig. 1K ,L) and increase in SA-b-gal activity (Fig. 1M,N) . Together, the results suggest that PAI-1 plays an important role in bleomycin-induced ATII cell senescence and that PAI-1 promotes ATII cell senescence at least in part by increasing p53 and thus p21, leading to a suppression of Rb protein phosphorylation.
Inhibition of PAI-1 activity with a small molecular PAI-1 inhibitor TM5275 attenuates bleomycin-induced p53 expression and L2 cell senescence TM5275 is a small molecule PAI-1 inhibitor, which, we have shown previously, blocks lung fibrosis in a bleomycin-induced lung injury model (Disayabutr et al., 2016) . To determine whether inhibition of PAI-1 activity with TM5275 also protects ATII cells from bleomycin-induced senescence, L2 cells were treated with 50 mU of bleomycin in the presence or absence of TM5275 (25 lM) for 24 h and then cultured in bleomycin-free medium for additional 72 h. The results show that treatment of L2 cells with TM5275 significantly reduces bleomycinstimulated p53 S18 phosphorylation, p53 and p21 expressions, as well as SA-b-gal activity ( Fig. 2A-G) . Our data also show that TM5275 reduces bleomycin-stimulation increase in the ratios of p53 S18P to p53 (Fig. 2C,2F ), further supporting the notion that PAI-1 stimulates p53 serine 18 phosphorylation.
Silencing PAI-1 with PAI-1 shRNA suppresses doxorubicininduced L2 cell senescence Doxorubicin (Dox) is another anticancer drug which induces senescence in different types of cells (Ghosh et al., 2016) . Although the major toxicity of doxorubicin is in cardiovascular system, several studies have shown that doxorubicin therapy causes interstitial pneumonia and fibrosis in patients (Junqueira et al., 1979; Kunz et al., 1995; Kortlever et al., 2006) . To determine whether doxorubicin induces ATII cell senescence and the role of PAI-1 in this process, L2 cells that have been stably transfected with PAI-1 shRNA or NT shRNA were treated with doxorubicin or saline. Similar to PAI-1 siRNA (Fig. 1C) , silencing PAI-1 with PAI-1 shRNA decreases the basal levels of p53 protein in L2 cells (Fig. 3A,C) . Silencing PAI-1 also diminishes doxorubicin-induced p53 and p21 expressions (Fig. 3A-D) as well as SA-b-gal activity (Fig. 3E,F) . The results suggest that doxorubicin induces ATII cell senescence and that PAI-1 mediates doxorubicin-induced ATII cell senescence at least in part by increasing p53.
Silencing p53 abrogates PAI-1 protein-induced L2 cell senescence
To further delineate the cause-effect relation between PAI-1 and p53 in ATII cell senescence, L2 cells were transfected with p53 siRNA or nontarget siRNA and then treated with active human PAI-1 protein (hPAI-1, Molecular Innovation). The results show that treatment of L2 cells with hPAI-1 increases PAI-1 mRNA (Fig. 4A ) as well as p53 and p21 proteins, which is associated with an suppression of Rb protein phosphorylation ( Fig. 4B ) and an increase in SA-b-gal activity (Fig. 4C,  D) . These data confirm that PAI-1 activates p53-p21-Rb pathway and induces ATII cell senescence. The results also suggest that PAI-1 induces the expression of its own gene (autocrine function). Silencing p53 with p53 siRNA, on the other hand, reduces the basal level of PAI-1 protein and increases the basal level of Rb phosphorylation ( Fig. 4E-I ). These results suggest that p53 positively regulates PAI-1 expression in ATII cells and that there is a feedforward relation between p53 and PAI-1. Importantly, silencing p53 significantly reduces hPAI-1-mediated increases in p21 protein expression (Fig. 4E , H) and completely blocks hPAI-1-induced SA-b-gal activity (Fig. 4C,D) . These results indicate that p53 functions as a downstream effector in PAI-1-induced ATII cell senescence, although it also regulates PAI-1 expression.
Deletion of PAI-1 specifically in ATII cells in mice protects ATII cells from bleomycin-induced senescence in vivo
To determine whether increased PAI-1 is responsible for ATII cell senescence in fibrotic lung disease in vivo, a tamoxifen (Tmx) inducible, ATII cell-specific PAI-1 conditional knockout (Sftpc-CreER:PAI-1 fl/fl
; CKO) mouse model has been generated by gene targeting technique as deciphered in Fig. S1 (Supporting information). PCR results show that Tmx injection induces a deletion of the exons 4&5 in the PAI-1 gene specifically in CKO mice (Fig. S2A , Supporting information). Immunofluorescence and Western analyses further confirm that Tmx injection almost completely knocks out PAI-1 protein in ATII cells in CKO mice (Fig. S2B ,C, Supporting information). The results suggest that we have successfully generated tamoxifen-inducible, ATII cell-specific PAI-1 conditional knockout mouse model.
To test whether deletion of PAI-1 specifically in ATII cells in mice will protect ATII cells from bleomycin-induced senescence in vivo (Leung hand, significantly reduces bleomycin-stimulated increases in PAI-1/p53-, p21-, or SA-b-gal-positive ATII cells (Fig. 5A-F ). Western analyses with isolated ATII cells further show that deletion of PAI-1 specifically in ATII cells in mice attenuates bleomycin-stimulated increases in p53 S18 phosphorylation (Fig. 5G,I ) as well as the expression of p53 and p21 proteins (Fig. 5G,J,L) . The ratios of p53 S18P to p53 is significantly increased following bleomycin treatment and returned to control level with deletion of PAI-1 (Fig. 5G,K) , suggesting that PAI-1 stimulates p53 S18 phosphorylation in vivo as well. Consistent with the results from cultured L2 cells, deletion of PAI-1 alone increases Rb phosphorylation in ATII cells in mice (Fig. 5G,M) . The effects of PAI-1 deletion on bleomycininduced p53 and p21 expressions in ATII cells are also confirmed by double immunostaining of mouse lung tissues ( Fig. 5N-S) . These results provide strong evidence, for the first time, that increased PAI-1 mediates bleomycin-induced p53 expression and ATII cell senescence in lung fibrosis in vivo.
Deletion of PAI-1 specifically in ATII cells in mice reduces PAI-1 protein in BAL fluid and attenuates bleomycin-induced lung fibrosis ATII cells have been shown to play a central role in the development of lung fibrosis (Lijnen, 2005; Chao, 2015; Li & Kurokawa, 2015) . To determine whether deletion of PAI-1 specifically in ATII cells protects mice from bleomycin-induced lung fibrosis, 8-to 10-week-old CKO and wild-type (PAI-1 fl/fl ) mice were injected with tamoxifen, challenged with 2 U/kg bleomycin, and euthanized 14 days after bleomycin instillation. The results show that specifically knocking out the PAI-1 gene in ATII cells in mice attenuates bleomycin-induced body weight loss (Fig. 6A) and PAI-1 accumulation in bronchoalveolar lavage fluid (BALF) (Fig. 6B) , although it has no significant effect on the body weight and BALF PAI-1 level of unchallenged mice. Deletion of PAI-1 specifically in ATII cells in mice also attenuates bleomycinstimulated increases in collagen deposition (Fig. 6C,D) , hydroxyproline accumulation (Fig. 6E) , and expression of procollagen 1a2 and procollagen 1a1 as well as alpha-smooth muscle actin (a-SMA) (Fig. 6F-I ) in mouse lungs. Together, the results suggest that ATII cells are an important source of BALF PAI-1 in fibrotic lung and that ATII cell senescence contributes importantly to the development of lung fibrosis.
Discussion
Fibrosis is a common pathological feature of many lung diseases, including IPF, an aging-related progressive fatal lung disorder with unknown etiology (Maclaine & Hupp, 2011; Mark & Thurlimann, 2012) . There is no cure for these fibrotic diseases due to incomplete understanding of the pathogenesis. ATII cells are progenitor cells of the alveolar epithelium; ATII cell senescence is evident in IPF and in experimental lung fibrosis models (Buckbinder et al., 1995; Chang et al., 2010; Bhandary et al., 2013; Barkauskas & Noble, 2014; Chao, 2015; Childs et al., 2015) . The mechanism underlying ATII cell senescence in fibrotic lung diseases, however, is unknown. Using IPF lung tissues, cultured ATII (L2) cells, and a PAI-1 conditional knockout mouse model, we show, for the first time in this study, that PAI-1 induces and mediates bleomycin-and doxorubicininduced ATII cell senescence in vitro and in vivo. Our data also show that suppression of bleomycin-induced ATII cell senescence in mice by specifically knocking out the PAI-1 gene in these cells is associated with attenuation of lung fibrosis. These results suggest that elevation of PAI-1 contributes importantly to ATII cell senescence in fibrotic lung diseases.
Although PAI-1 has been shown to induce cell senescence in different types of cells (Fernandez Perez et al., 2010; Eren et al., 2014a,b; Ghosh et al., 2016) , the molecular mechanism whereby PAI-1 promotes cell senescence remains poorly understood. p53 plays a central role in the induction of cellular senescence (Marudamuthu et al., 2015) , mainly through inducing p21, an inhibitor of cyclin-dependent kinases (CDKs), leading to dephosphorylation and activation of cell cycle repressor retinoblastoma (Rb). In this study, we show, for the first time, that PAI-1 protein increases, whereas PAI-1 siRNA/shRNA and PAI-1 inhibitor TM5275 suppress bleomycin-and/or doxorubicin-induced, p53 and p21 expressions as well as SA-b-gal activity in cultured ATII (L2) cells and in mouse lung ATII cells in vivo. This is associated with a decrease (by PAI- 1 protein or bleomycin) and an increase (by PAI-1 siRNA/shRNA) in Rb phosphorylation, respectively. Silencing p53 in L2 cells, on the other hand, dramatically reduces PAI-1 protein-induced p21 expression and L2 cell senescence. Our data strongly suggest that PAI-1 induces ATII cell senescence, at least in part, through increasing p53 expression and activating p53-p21-Rb cell cycle repression pathway. This is first report showing that PAI-1 positively regulates p53 expression in epithelial cells. We want to stress that the effects of PAI-1 on p53 expression seem to be cell type specific (Disayabutr et al., 2016; Ghosh et al., 2016) . We showed in a previous study that a small molecule PAI-1 inhibitor TM5275 induced p53 in fibroblasts (Disayabutr et al., 2016) . A recent study from a different laboratory demonstrated, on the other hand, that PAI-1 inhibitor TM5441 suppressed doxorubicin-induced p53 expression in endothelial cells (Ghosh et al., 2016) . The results from this study further confirm the complexity of cell type-dependent regulation of p53 expression by PAI-1. The mechanism whereby PAI-1 increases p53 protein in ATII cells is currently unknown. Posttranslational modifications, including phosphorylation and ubiquitination, play a critical role in p53 protein stability and transactivation function (Huang et al., 2012; Marzec et al., 2015) . Phosphorylation of p53 at serine 15 and serine 20 (serine 18 and serine-23 in rodents) prevents the binding of p53 to murine double minute 2 (MDM2), a major E3 ubiquitin ligase involved in p53 degradation, and thereby stabilizes p53 protein (Huang et al., 2012 (Huang et al., , 2015 . Our studies show that treatment of rat ATII (L2) cells with PAI-1 protein increases, whereas silencing PAI-1 with PAI-1 shRNA or inhibition of PAI-1 activity with a small molecule PAI-1 inhibitor TM5275 decreases, p53 phosphorylation at serine-18 residue, suggesting that PAI-1 increases p53 protein probably by increasing p53 serine 15 and/or serine 20 phosphorylation and thereby suppressing its degradation. More studies are needed to determine the molecular mechanism whereby PAI-1 suppresses p53 phosphorylation and potentially degradation in these cells.
It should be stressed that p53 has been shown to regulate PAI-1 expression in different types of cells (Osterholzer et al., 2011; Nevadunsky et al., 2013; Mohapatra et al., 2016) . It has also be reported that PAI-1 functions downstream of p53 in replicative senescence of cultured fibroblasts (Eren et al., 2014a) . In this study, we show that silencing p53 with p53 siRNA reduces the basal level of PAI-1 and attenuates PAI-1 protein-induced PAI-1 expression in L2 cells (Fig. 4) , further supporting the notion that p53 regulates PAI-1 expression. However, using both pharmacological and genetic approaches, we show in this study that PAI-1 induces p53 and activates p53/p21/Rb pathways in ATII cells fl/fl in vitro and in vivo. Silencing p53 almost completely abolishes PAI-1 protein-induced p21 expression and L2 cell senescence. These data strongly suggest that PAI-1 induces p53 and that p53 functions downstream of PAI-1 in the induction of ATII cell senescence. We also want to mention that, besides inducing senescence, PAI-1 also plays a role in apoptosis. Although increased PAI-1 has been shown in almost all types of senescent cells studied, effects of PAI-1 on apoptosis sensitivity are cell type-dependent. It has been reported that increased PAI-1 expression is associated with increased sensitivity of ATII cells to apoptosis (Osterholzer et al., 2011; Hogan et al., 2014; Schafer et al., 2017) but increased apoptosis resistance in fibroblasts (El-Deiry et al., 1992; Serrano-Mollar et al., 2007; Citrin et al., 2013; Disayabutr et al., 2016) . More studies are needed to understand the mechanism whereby PAI-1 differentially regulates p53 expression and apoptosis sensitivity in different types of cells. Insulin-like growth factor binding protein 3 (IGFBP3) is a major insulin growth factor (IGF) binding protein, which binds to IGF and inhibits its signaling. IGFBP3 expression is increased in senescent cells and is believed to mediate cell senescence in different types of cells (Fernandez Perez et al., 2010; Eren et al., 2014b; Ghosh et al., 2016) . Interestingly, it has been reported that PAI-1 promotes senescence in MCF-7 breast cancer cells by inhibiting tPA-mediated proteolysis of IGFBP3 (Eren et al., 2014b) . Increased PAI-1 expression has also been shown to be responsible for the increase in IGFBP3 expression, cell senescence, and lifespan shortening in Klotho-deficient (kl/kl) mice, a murine aging model (Fernandez Perez et al., 2010) . Consensus sites for p53 binding have been identified in intronic regions of the IGFBP3 gene and wild-type p53 increases IGFBP3 expression in response to DNA damage (Shetty et al., 2008 (Shetty et al., , 2012 Sisson et al., 2010) . These results suggest that IGFBP3 may functions downstream of PAI-1 and p53 in the induction of senescence. Whether PAI-1 induces IGFBP3 in ATII cells and whether PAI-1 induces ATII cell senescence by increasing p53 and thereby IGFBP3 remains to be determined.
PAI-1 expression is increased in lung fibrotic diseases including IPF and in experimental lung fibrosis models (El-Deiry et al., 1992; Dimri et al., 1995; Citrin et al., 2013; Disayabutr et al., 2016) . Which types of cells are the major contributors of PAI-1 in fibrotic lungs and how PAI-1 promotes lung fibrosis, however, remain to be determined. It has been reported that, in diphtheria toxin (DT)-induced ATII cell injury and fibrosis model, ATII cells and macrophages are the major contributors of PAI-1 in the alveolar compartment (Zappa et al., 2009) . Increased PAI-1 expression contributed to DT-induced ATII cell injury and lung fibrosis as knockout of the PAI-1 gene attenuated DT-induced ATII cell injury and lung fibrosis (Zappa et al., 2009) . Using tamoxifen-inducible ATII cellspecific PAI-1 knockout mouse model, we show, in this study, that knockout of the PAI-1 gene specifically in ATII cells in mice significantly attenuates bleomycin-stimulated increase in BALF PAI-1 protein, although it has no significant effect on the basal level of PAI-1 in BALF. Our results also show that deletion of the PAI-1 gene in ATII cells alone significantly reduces bleomycin-induced accumulation of collagen and hydroxyproline in mouse lung. These data suggest that ATII cells are important source of BALF PAI-1 in fibrotic lung, although they are not the major contributors of BALF PAI-1 under unchallenged/normal condition. These data also suggest that ATII cell PAI-1 plays a pivotal role in the development of lung fibrosis and that PAI-1 promotes lung fibrosis in part by inducing ATII cell senescence. Further studies are warranted to determine how senescent ATII cells contribute to the development of lung fibrosis and the role of PAI-1 in this process.
In summary, we demonstrate here, for the first time, that PAI-1 induces p53, activates p53-p21-Rb cell cycle repression pathway, and promotes senescence in ATII cells in vitro and in vivo. These findings may have a significant impact on the research beyond lung fibrosis as PAI-1 expression is increased with age and in many aging-related pathological conditions.
Experimental procedures
Generation of PAI-1 conditional knockout mice See supplementary material (Fig. S1, Supporting information) for the details. Western blotting and immunofluorescence staining techniques were used to confirm Tmx-inducible PAI-1 conditional knockout phenotype in isolated ATII cells after mice were injected with tamoxifen or oil (Fig. S2, Supporting information) . All procedures involving animals were approved by the Institutional Animal Care and Use Committees at the University of Alabama at Birmingham and conducted at the UAB animal facilities under specific pathogen-free conditions.
Cell culture and treatment L2 cells, originally derived from type II pneumocytes of adult rat lungs, were obtained from the American Type Culture Collection (Rockville, MD) and cultured with Ham's F-12 medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin, and 100 lg/mL streptomycin at 5% CO 2 and 37°C.
Establishment of PAI-1 knockdown ATII cell line L2 cells were stably transduced with nontarget shRNA retrovirus or PAI-1 shRNA retrovirus (Origene, Cat No TR30013 and TF709263, respectively) according to the manufacturer's instructions. Briefly, retrovirus vector pGFP-V-RS-Control shRNA or pGFP-V-RS-rat PAI-1 shRNA was transfected into Phoenix-AMPHO retrovirus package cells. The supernatant containing the viruses was harvested 48 h posttransfection to infect L2 cells. At 24 h postinfection, transduced cells were selected with 1 lg/mL puromycin for 1 week. PAI-1 protein was determined by Western blotting to confirm the knockdown phenotype.
Induction of lung fibrosis and collection of samples
Eight-to 10-week-old male PAI-1 fl/fl (WT control) and Sftpc-CreER:PAI-1 fl/fl mice were intraperitoneally injected with 100 mg/kg Tmx for 7 days and then challenged with 2 U/kg of bleomycin (dissolved in saline) or saline alone through oropharyngeal instillation. Mice were euthanized 14 days after challenge. Bronchoalveolar lavage (BAL) was performed and pulmonary artery vascular beds perfused as we have described previously (El-Deiry et al., 1992; Disayabutr et al., 2016) . Left lung was then fixed with 10% PBS-buffered formalin and the rest of the lung frozen immediately in liquid nitrogen for biochemistry analyses as we have described previously (Disayabutr et al., 2016) .
Isolation of ATII cells from mouse lung
Mouse lung ATII cells were isolated following the protocol described previously (Zhang et al., 2012 ) with a few modifications. Briefly, mouse lungs were instilled with 2 mL protease solution (300 U/mL collagenase type I, 4 U/mL elastase, 5 U/mL dispase, and 100 lg/mL DNase I in HBSS), minced by razor, and incubated at 37°C for 25 min. Digestion was stopped with 50% DMEM/50% F12 containing 3% fetal bovine serum and suspension washed in HBSS and then incubated with 2 mL HBSS containing 0.1% trypsin-EDTA, 100 lg/mL DNase I for 20 min at 37°C.
Following tissue dissociation, cell suspensions were filtered through a 40-lm nylon mesh, washed, and treated with ACK (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) solution to lyse red blood cells and then suspended in DMEM/F12 medium containing 1% fetal bovine serum. Macrophages and lymphocytes were removed by incubation with biotinylated rat antimouse CD45 and rat anti-mouse CD16/32. (BD Biosciences). The cells were then cultured in DMEM/F-12 medium containing 10% FBS in 100-mm culture dishes at 37°C for 2 h to remove lung fibroblasts. The suspended ATII cells were harvested for further analysis. Immunostaining with anti-SPC antibody confirms that >90% cells are ATII cells.
Immunofluorescence staining
To reveal PAI-1, p53, and p21 proteins in mouse lung tissue, double immunostaining was conducted using formalin-fixed, paraffinembedded tissue slides with antibodies to mouse PAI-1 ( Measurement of the activity of senescence associated betagalactosidase (SA-b-gal) 
